Pharmacotherapy for Dravet Syndrome

Pediatric Drugs

Volumn 18, Issue 3, 2016, Pages 197-208

  Wallace, Adam ^a   Wirrell, Elaine ^a   Kenney Jung, Daniel L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMIDE; CANNABIDIOL; CARBAMAZEPINE; CLOBAZAM; FENFLURAMINE; LAMOTRIGINE; LEVETIRACETAM; MEDICAL CANNABIS; PSYCHOSTIMULANT AGENT; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT;

ATTENTION DEFICIT DISORDER; CHILDHOOD MORTALITY; DRUG CONTRAINDICATION; DRUG RESISTANT EPILEPSY; EPILEPTIC STATE; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GENE; GENE MUTATION; HUMAN; KETOGENIC DIET; MOTOR PERFORMANCE; NERVE STIMULATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCN1A GENE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TREATMENT INDICATION; CHILD; EPILEPSIES, MYOCLONIC; EPILEPSY; MUTATION; SEIZURES;

ANTICONVULSANTS; CHILD; EPILEPSIES, MYOCLONIC; EPILEPSY; HUMANS; MUTATION; QUALITY OF LIFE; SEIZURES;

EID: 84960358127     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-016-0171-7     Document Type: Review

References (93)

1. Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(Pt 8):2329–36. doi:10.1093/brain/aws151.
2. Bayat A, Hjalgrim H, Moller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia. 2015. doi:10.1111/epi.12927.
3. Cheah CS, Yu FH, Westenbroek RE, Kalume FK, Oakley JC, Potter GB, et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA. 2012;109(36):14646–51. doi:10.1073/pnas.1211591109.
4. Yamakawa K. Molecular and cellular basis: insights from experimental models of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):70–1. doi:10.1111/j.1528-1167.2011.03006.x.
5. Liu Y, Lopez-Santiago LF, Yuan Y, Jones JM, Zhang H, O’Malley HA, et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol. 2013;74(1):128–39. doi:10.1002/ana.23897.
6. Chopra R, Isom LL. Untangling the dravet syndrome seizure network: the changing face of a rare genetic epilepsy. Epilepsy Curr. 2014;14(2):86–9. doi:10.5698/1535-7597-14.2.86.
7. Bureau M, Bernardina BD. Electroencephalographic characteristics of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):13–23. doi:10.1111/j.1528-1167.2011.02996.x.
8. Dravet C, Bureau M, Bernardina BD, Guerrini R. Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later. Epilepsia. 2011;52(Suppl 2):1–2. doi:10.1111/j.1528-1167.2011.02993.x.
9. Chieffo D, Battaglia D, Lettori D, Del Re M, Brogna C, Dravet C, et al. Neuropsychological development in children with Dravet syndrome. Epilepsy Res. 2011;95(1–2):86–93. doi:10.1016/j.eplepsyres.2011.03.005.
10. Wolff M, Casse-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia. 2006;47(Suppl 2):45–8. doi:10.1111/j.1528-1167.2006.00688.x.
11. Ragona F, Granata T, Dalla Bernardina B, Offredi F, Darra F, Battaglia D, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia. 2011;52(2):386–92. doi:10.1111/j.1528-1167.2010.02925.x.
12. Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, Dubouch C, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176. doi:10.1186/1750-1172-8-176.
13. Gaily E, Anttonen AK, Valanne L, Liukkonen E, Traskelin AL, Polvi A, et al. Dravet syndrome: new potential genetic modifiers, imaging abnormalities, and ictal findings. Epilepsia. 2013;54(9):1577–85. doi:10.1111/epi.12256.
14. Specchio N, Balestri M, Trivisano M, Japaridze N, Striano P, Carotenuto A, et al. Electroencephalographic features in dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol. 2012;27(4):439–44. doi:10.1177/0883073811419262.
15. Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr. Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol. 2007;22(2):185–94. doi:10.1177/0883073807300294.
16. Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52(Suppl 2):44–9. doi:10.1111/j.1528-1167.2011.03001.x.
17. Takayama R, Fujiwara T, Shigematsu H, Imai K, Takahashi Y, Yamakawa K, et al. Long-term course of Dravet syndrome: a study from an epilepsy center in Japan. Epilepsia. 2014;55(4):528–38. doi:10.1111/epi.12532.
18. Akiyama M, Kobayashi K, Yoshinaga H, Ohtsuka Y. A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia. 2010;51(6):1043–52. doi:10.1111/j.1528-1167.2009.02466.x.
19. Catarino CB, Liu JY, Liagkouras I, Gibbons VS, Labrum RW, Ellis R, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain. 2011;134(Pt 10):2982–3010. doi:10.1093/brain/awr129.
20. Sanchez-Carpintero R, Patino-Garcia A, Urrestarazu E. Musicogenic seizures in Dravet syndrome. Dev Med Child Neurol. 2013;55(7):668–70. doi:10.1111/dmcn.12138.
21. Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627–33. doi:10.1016/b978-0-444-52891-9.00065-8.
22. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508–12.
23. Tanabe T, Awaya Y, Matsuishi T, Iyoda K, Nagai T, Kurihara M, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)—a nationwide questionnaire survey in Japan. Brain Dev. 2008;30(10):629–35. doi:10.1016/j.braindev.2008.03.002.
24. Bromfield EB, Dworetzky BA, Wyszynski DF, Smith CR, Baldwin EJ, Holmes LB. Valproate teratogenicity and epilepsy syndrome. Epilepsia. 2008;49(12):2122–4. doi:10.1111/j.1528-1167.2008.01696.x.
25. Valproic Acid [database on the Internet]. Truven health analytics. 2015. http://micromedex.com/
26. Inoue Y, Ohtsuka Y, Oguni H, Tohyama J, Baba H, Fukushima K, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362–8. doi:10.1111/j.1528-1167.2009.02179.x.
27. Dressler A, Trimmel-Schwahofer P, Reithofer E, Muhlebner A, Groppel G, Reiter-Fink E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome—comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–9. doi:10.1016/j.eplepsyres.2014.10.014.
28. Product informatin: ONFI (R) oral tablets, suspension, clobazam oral tablets, suspension. Deerfield: Lundbeck (per FDA); 2012.
29. Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T, Tanikawa K, et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. Ther Drug Monit. 2014;36(3):302–9. doi:10.1097/ftd.0000000000000015.
30. Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics. 2008;9(5):527–37. doi:10.2217/14622416.9.5.527.
31. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos Biol Fate Chem. 2006;34(4):608–11. doi:10.1124/dmd.105.007237.
32. Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. Clin Pharmacokinet. 2015;54(5):527–36. doi:10.1007/s40262-014-0223-5.
33. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology. 1999;52(7):1338–44.
34. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol. 2000;15(Suppl 1):S7–13.
35. Rosenfeld WE. Topiramate. In: Wyllie E, Cascino G, Gidal B, Goodkin H, editors. Wyllie’s treatment of epilepsy. 5th ed. Philadephia: Wolters Kluwer/Lippincott Williams and Wilkins; 2011. p. 710–22.
36. Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590–4. doi:10.1053/seiz.2000.0466.
37. Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49(1):45–8.
38. Kroll-Seger J, Portilla P, Dulac O, Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325–9. doi:10.1055/s-2007-964867.
39. Takahashi H, Takahashi Y, Mine J, Mukaida S, Ikegami M, Ikeda H, et al. Effectiveness of topiramate in eleven patients with Dravet syndrome. No To Hattatsu. 2010;42(4):273–6.
40. Tran A, Rey E, Pons G, Rousseau M, d’Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490–504. doi:10.1016/S0009-9236(97)90044-8.
41. Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52(Suppl 2):76–8. doi:10.1111/j.1528-1167.2011.03008.x.
42. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006;47(4):704–16. doi:10.1111/j.1528-1167.2006.00497.x.
43. Grosenbaugh DK, Mott DD. Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine-refractory status epilepticus. Neuropharmacology. 2013;67:136–43. doi:10.1016/j.neuropharm.2012.11.002.
44. Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2015. doi:10.1002/jnr.23688.
45. Auvin S, Lecointe C, Dupuis N, Desnous B, Lebon S, Gressens P, et al. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia. 2013;54(12):2082–90. doi:10.1111/epi.12401.
46. Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190–7. doi:10.1016/j.neuropharm.2008.06.004.
47. Chiron C, Marchand MC, Tran A, Rey E, d’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638–42.
48. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet’s syndrome). Arch Pediatr. 2002;9(11):1120–7.
49. Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective US study. Epilepsia. 2013;54(9):1595–604. doi:10.1111/epi.12303.
50. Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90–7. doi:10.1016/j.eplepsyres.2015.03.012.
51. Sirven JI, Drazkowski JF. Levetiracetam. In: Wyllie E, Cascino G, Gidal B, Goodkin H, editors. Wyllie’s treatment of epilepsy. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2011. p. 731–5.
52. Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250–4. doi:10.1212/01.wnl.0000265222.24102.db.
53. Chhun S, Troude P, Villeneuve N, Soufflet C, Napuri S, Motte J, et al. A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. Seizure. 2011;20(4):320–5. doi:10.1016/j.seizure.2010.12.017.
54. Uthman BM. Less commonly used antiepileptic drugs. In: Wyllie E, Cascino G, Gidal B, Goodkin H, editors. Wyllie’s treatment of epilepsy. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2011. p. 779–89.
55. Oguni H, Hayashi K, Oguni M, Mukahira A, Uehara T, Fukuyama Y, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35(6):1140–5.
56. Lotte J, Haberlandt E, Neubauer B, Staudt M, Kluger GJ. Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43(1):17–21. doi:10.1055/s-0032-1307454.
57. Hartman AL, Gasior M, Vining EP, Rogawski MA. The neuropharmacology of the ketogenic diet. Pediatr Neurol. 2007;36(5):281–92. doi:10.1016/j.pediatrneurol.2007.02.008.
58. Kang HC, Kim YJ, Kim DW, Kim HD. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia. 2005;46(2):272–9. doi:10.1111/j.0013-9580.2005.48504.x.
59. Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54–7. doi:10.1111/j.1528-1167.2011.03107.x.
60. Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011;52(Suppl 2):79–82. doi:10.1111/j.1528-1167.2011.03009.x.
61. Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol. 2013;28(8):1041–4. doi:10.1177/0883073813487599.
62. Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013;19(3 Epilepsy):756–766. doi:10.1212/01.CON.0000431396.23852.
63. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283(13):1703–9.
64. Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc. 2000;75(5):456–61. doi:10.4065/75.5.456.
65. Boel M, Casaer P. Add-on therapy of fenfluramine in intractable self-induced epilepsy. Neuropediatrics. 1996;27(4):171–3. doi:10.1055/s-2007-973781.
66. Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131–9. doi:10.1111/j.1528-1167.2012.03495.x.
67. 2+ -Induced Epileptiform Activity in Rat Entorhinal Cortex. Epilepsia. 2000;41(8):925–8. doi:10.1111/j.1528-1157.2000.tb00273.x.
68. Fenfluramine [database on the Internet]. Truven health analytics. 2015. http://micromedex.com/
69. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802. doi:10.1111/epi.12631.
70. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–8. doi:10.1016/S1474-4422(15)00379-8.
71. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–7. doi:10.1016/j.yebeh.2013.08.037.
72. Press C, Knupp K, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49–52. doi:10.1016/j.yebeh.2015.02.043.
73. Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138–41. doi:10.1016/j.yebeh.2015.04.009.
74. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–51. doi:10.1111/epi.13060.
75. Bremer A, Lossius MI, Nakken KO. Dravet syndrome—considerable delay in making the diagnosis. Acta Neurol Scand. 2012;125(5):359–62. doi:10.1111/j.1600-0404.2011.01609.x.
76. Fridley J, Reddy G, Curry D, Agadi S. Surgical treatment of pediatric epileptic encephalopathies. Epilepsy Res Treat. 2013;2013:11. doi:10.1155/2013/720841.
77. Zamponi N, Passamonti C, Cappanera S, Petrelli C. Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol. 2011;15(1):8–14. doi:10.1016/j.ejpn.2010.09.003.
78. Orosz I, McCormick D, Zamponi N, Varadkar S, Feucht M, Parain D, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia. 2014;55(10):1576–84. doi:10.1111/epi.12762.
79. Andrade DM, Hamani C, Lozano AM, Wennberg RA. Dravet syndrome and deep brain stimulation: seizure control after 10 years of treatment. Epilepsia. 2010;51(7):1314–6. doi:10.1111/j.1528-1167.2009.02408.x.
80. Sakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S, et al. Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia. 2011;52(6):1144–9. doi:10.1111/j.1528-1167.2011.03053.x.
81. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus—report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515–23. doi:10.1111/epi.13121.
82. Chipaux M, Villeneuve N, Sabouraud P, Desguerre I, Boddaert N, Depienne C, et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure. 2010;19(3):190–4. doi:10.1016/j.seizure.2010.01.007.
83. Riva D, Vago C, Pantaleoni C, Bulgheroni S, Mantegazza M, Franceschetti S. Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes. Am J Med Genet Part A. 2009;149A(10):2339–45. doi:10.1002/ajmg.a.33029.
84. Harkin LA, McMahon JM, Iona X, Dibbens L, Pelekanos JT, Zuberi SM, et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 2007;130(Pt 3):843–52. doi:10.1093/brain/awm002.
85. Miller IO, Sotero de Menezes MA. SCN1A-related seizure disorders. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle: University of Washington; 1993.
86. Koneski JA, Casella EB, Agertt F, Ferreira MG. Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review. Epilepsy Behav. 2011;21(3):228–32. doi:10.1016/j.yebeh.2011.02.029.
87. Santos K, Palmini A, Radziuk AL, Rotert R, Bastos F, Booij L, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol. 2013;55(7):654–60. doi:10.1111/dmcn.12121.
88. Catarino CB, Liu JYW, Liagkouras I, Gibbons VS, Labrum RW, Ellis R, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain. 2011;134(10):2982–3010. doi:10.1093/brain/awr129.
89. Rodda JM, Scheffer IE, McMahon JM, Berkovic SF, Graham HK. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69(7):873–8. doi:10.1001/archneurol.2011.3275.
90. Rilstone JJ, Coelho FM, Minassian BA, Andrade DM. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53(8):1421–8. doi:10.1111/j.1528-1167.2012.03583.x.
91. Fasano A, Borlot F, Lang AE, Andrade DM. Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. Neurology. 2014;82(24):2250–1. doi:10.1212/wnl.0000000000000521.
92. Nabbout R, Gennaro E, Dalla Bernardina B, Dulac O, Madia F, Bertini E, et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology. 2003;60(12):1961–7.
93. Sugawara T, Mazaki-Miyazaki E, Fukushima K, Shimomura J, Fujiwara T, Hamano S, et al. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology. 2002;58(7):1122–4.